NCT03187444Active, not recruiting
Cardiovascular Risk and Chronic Inflammatory Rheumatism
Source: ClinicalTrials.gov · Last updated 25 May 2022
Brief summary (registry, in English)
Chronic inflammatory rheumatism and inflammation can increase the risk of cardiovascular problems. Indeed, these diseases can increase the risk of myocardial infarction. The objective of this project is a better understanding and preventing the risk of cardiovascular problems in chronic inflammatory rheumatism through the study on the long-term flexibility of the arteries, blood markers of cardiovascular risk and muscle mass.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 7 Jun 2017
- Start date
- 24 Apr 2015
- Primary completion date
- 24 Oct 2036
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT03187444
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 24 Apr 2015 to the primary completion date, 24 Oct 2036
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with chronic disease may interfere with cardiovascular disease either by itself or by treatment history
- For echocardiography high resolution STI: Patients with hypertension, diabetes and cardiovascular history.
- To evaluate the activity of the autonomic nervous system, patients with hypertension, diabetics, with cardiovascular history with a neurological disease, with vasoactive or chronotropic treatments such as beta-blockers, antiarrhythmics, antihypertensives, anxiolytics, antidepressants
Other
- Patient refused to sign the consent form
- Patient under guardianship
- Patient having already been exposed to a biological as part of its pathology
- Pregnant or lactating women will be temporarily excluded from the study during the period of pregnancy and breastfeeding.
Who the study is looking for
- Being older than 18 years
- Have rheumatoid arthritis or spondyloarthritis (ankylosing spondylitis, psoriatic arthritis)
- Receive first conventional DMARD or biological treatment (anti-TNF, Abatacept, Tocilizumab, rituximab) for patients with rheumatoid arthritis
- Receive biological treatment (Abatacept, Tocilizumab, rituximab) for patients with rheumatoid arthritis who have failed anti-TNF treatment.
- Receive first NSAID (optionally combined with conventional DMARDs in case of peripheral arthritis) or biological treatment (anti-TNF, Usketinumab) for patients with spondyloarthritis.
- Being subject to a social security scheme
- Have the capacity to give informed consent and to comply with the study requirements
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Clermont-Ferrand Coordinator of this site? Confirm its status | Clermont-Ferrand | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.